NEWPORT NEWS, Virginia, July 10, 2014 /PRNewswire/ -- Dilon Technologies, leader in molecular imaging cameras including Molecular Breast Imaging (MBI/BSGI), announced today that it obtained CE Mark approval for its Navigator® Gamma Probe system. The CE Mark allows Dilon to begin marketing the device throughout the European Union. Dilon has expanded its distribution into the majority of European countries and has already received the first orders.
"The Navigator Gamma Probe has been strongly accepted by surgeons in the United States. Three major influences for surgeon acceptance has been the strong reliability, simple design and ease of operation" stated Robert Moussa, Dilon's President and CEO. "A comparable market response is anticipated for Europe and other countries around the world that recognize the CE Mark."
The Navigator Gamma Probe system is used in radio-guided surgical procedures, primarily for lymphatic mapping and tumor localization. Over the last several decades, procedures such as sentinel lymph node mapping, first in melanoma, and more recently in breast, have become a gold standard of care among general surgeons and surgical oncologists. Additional applications for the Navigator Gamma Probes are in pulmonary wedge resection, parathyroid adenoma, and laparoscopy.
Dilon Technologies® Inc. strives to improve the quality of life by providing a wide range of innovative medical solutions that benefit patients around the world. Dilon is a leader in diagnostic imaging with the Dilon Molecular Imaging Systems, high-resolution, small field-of-view general-use molecular imaging cameras, optimized to perform Molecular Breast Imaging (MBI/BSGI) and localization for MBI-guided breast biopsy. Dilon's cornerstone surgical imaging products, the Navigator® Probes, are one of the most widely used gamma probes for cancer surgery in the marketplace. The gamma probes offer a revolutionary upgrade option for 3D Tumor Imaging and Navigation with SurgicEye's declipseSPECT camera. Dilon is the exclusive international distributor of Digirad's Cardius® cardiac and ergo™ general molecular imaging cameras that provide outstanding image quality and increased patient comfort with a compact, open design. For more information visit www.dilon.com
Media contact: Pjerin Luli
SOURCE Dilon Technologies Inc.